Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms · Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 372 (planned)
- Started
- Mar 20, 2025
- Main results expected
- Dec 31, 2029
- Fully finished
- Mar 16, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Measured over: Up to ~43 weeks
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Measured over: Up to 21 days
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Measured over: Up to ~30 weeks
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Measured over: Up to ~30 weeks
Part 2: Number of Participants Experiencing an AE
Measured over: Up to ~103 weeks
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Measured over: Up to ~90 weeks
Changes Tremor has spotted
Moved the final finish date earlier: Dec 31, 2034 → Mar 16, 2031.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · date_moved_earlier · completion_date
old: "2034-12-31"
new: "2031-03-16"
details: {"months":-45.5}
Trial ID NCT06797635 · record last updated 2026-11-06 · checked 2026-11-09 06:30 UTC